Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
| Descriptor ID |
D002289
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
| Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 5 | 2 | 7 |
| 1993 | 10 | 1 | 11 |
| 1994 | 16 | 2 | 18 |
| 1995 | 9 | 3 | 12 |
| 1996 | 19 | 2 | 21 |
| 1997 | 21 | 2 | 23 |
| 1998 | 22 | 3 | 25 |
| 1999 | 29 | 4 | 33 |
| 2000 | 34 | 6 | 40 |
| 2001 | 49 | 5 | 54 |
| 2002 | 189 | 22 | 211 |
| 2003 | 208 | 37 | 245 |
| 2004 | 295 | 43 | 338 |
| 2005 | 381 | 49 | 430 |
| 2006 | 344 | 46 | 390 |
| 2007 | 408 | 42 | 450 |
| 2008 | 468 | 54 | 522 |
| 2009 | 527 | 62 | 589 |
| 2010 | 607 | 62 | 669 |
| 2011 | 739 | 56 | 795 |
| 2012 | 750 | 72 | 822 |
| 2013 | 867 | 77 | 944 |
| 2014 | 930 | 76 | 1006 |
| 2015 | 1025 | 73 | 1098 |
| 2016 | 1071 | 89 | 1160 |
| 2017 | 1093 | 82 | 1175 |
| 2018 | 1089 | 71 | 1160 |
| 2019 | 461 | 22 | 483 |
| 2020 | 29 | 5 | 34 |
| 2021 | 11 | 2 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
The Mechanisms of the Growth Inhibitory Effects of Paclitaxel on Gefitinib-resistant Non-small Cell Lung Cancer Cells. Cancer Genomics Proteomics. 2021 Sep-Oct; 18(5):661-673.
-
Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient. Int Immunopharmacol. 2021 Oct; 99:108012.
-
Alectinib continuation during COVID 19 'antiviral' treatment: Risk or benefit? J Oncol Pharm Pract. 2021 Jul; 27(5):1251-1254.
-
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as mortality predictor of advanced stage non-small cell lung cancer (NSCLC) with COVID-19 in Indonesia. Eur Rev Med Pharmacol Sci. 2021 05; 25(10):3868-3878.
-
Estimating the Impact of Extended Delay to Surgery for Stage I Non-small-cell Lung Cancer on Survival. Ann Surg. 2021 05 01; 273(5):850-857.
-
Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncol Pract. 2021 08; 17(8):e1235-e1245.
-
Predictive factors testing proposal for NSCLC patients during the COVID-19 pandemic. Expert Rev Anticancer Ther. 2021 06; 21(6):569-572.
-
Safety of current immune checkpoint inhibitors in non-small cell lung cancer. Expert Opin Drug Saf. 2021 Jun; 20(6):651-667.
-
Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021 03; 9(3).
-
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. Immunotherapy. 2021 04; 13(6):509-525.